The atopic dermatitis (AD) market is expected to grow from a value of $6.4 billion in 2020 to $16.8 billion in 2030 in the seven major markets at a compound ann 4 May 2022
French drugmaker Sanofi held an investor event this week to outline its ambitions in the immunology space, including the goal to more than quadruple sales in th 31 March 2022
At this year’s annual congress of the American Academy of Dermatology (AAD), Incyte (Nasdaq: INCY) has announced new one-year results for Opzelura (ruxolitinib) 28 March 2022
French drugmaker Sanofi and partner Regeneron have announced positive results from the Phase III PRIME2 trial of Dupixent (dupilumab) at the American Academy of 28 March 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.